Women are missing from medicines development: EMA’s roadmap for change

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This…, Women are still missing: from research and data, prevention, diagnosis and treatment.

But the momentum to improve support for women’s health has never been stronger.…, Meaningful change starts with dialogue and with a shared understanding of the challenges we face. We end this workshop with a clear path to action”, “National regulatory…, The multistakeholder…

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: News and press releases · September 30, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.